In breast cancer, inhibition of TRPM2 increased cell death after doxorubicin and tamoxifen (Koh et al., 2015), another commonly used chemotherapeutic agent in breast cancer therapy (Howell and Howell, 2023). The gene discussed is TRPM2; the disease is breast carcinoma.